On Monday, Glaxo and Genmab's new leukemia treatment drug Arzerra was awarded accelerated approval by the Food and Drug Administration. Marketing of the latest drug, which is designed to help leukemia patients who have stopped responding, or do not respond at all, to other treatments, will be undertaken by  GlaxoSmithKline PLC.